Purpose Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. 123 I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immunemediated diseases.
Introduction
Radiolabelled interleukin-2 (IL2) is a radiopharmaceutical designed for the in vivo study of chronic inflammatory diseases [1] . Previous studies with 123 I-labelled IL2 ( 123 I-IL2) in several patients with immune-mediated diseases showed specific targeting of tissues-infiltrated by activated lymphocytes; rapid clearance from the circulation through the kidneys was observed, and major organs of uptake were kidneys, liver and spleen with minimal intestinal excretion. No side effects were reported [2, 3] . Radiolabelled IL2 might be a useful radiopharmaceutical in different immune-mediated diseases: it might guide the diagnosis and treatment of the disease by providing relevant information about the presence of the ongoing inflammatory process. The efficacy of new, specific, anti-inflammatory drugs could also be tested. It would be necessary, however, to perform studies in an adequate number of patients to evaluate the clinical value of radiolabelled IL2 in different diseases. 123 I, however, is expensive and not readily available, and 99m Tc labelling of IL2 would be desirable for larger studies.
We have previously described a technique for 99m Tc labelling of IL2 using a N 3 S bifunctional chelating agent with purification by solid phase extraction [4] . The aim of this study was to describe the biodistribution and kinetics of 99m Tc-IL2 in normal subjects, the potential toxic profile and the radiation absorbed dose. We also studied the ability of 99m Tc-IL2 to detect in vivo areas of lymphocytic infiltration in a small number of patients affected by autoimmune thyroid disease.
Materials and methods

Preparation of 99m Tc-IL2
Radiolabelling of IL2 was carried out under aseptic conditions. Interleukin-2 was labelled with 99m Tc using a two-step pre-labelling method as previously described [4] using a bifunctional chelating agent with two functional sites: an N 3 S ring, similar to that of MAG3, for the stable coordination of 99m Tc, and an active ester for binding to proteins via the amino groups of lysine residues. Briefly, the ligand was first labelled to high specific activity with 99m Tc (3.7 GBq) in the presence of stannous chloride and gluconic acid at pH 2 at 80°C for 20 min. Radiolabelled ligand was then conjugated to IL2 (100 μg, 1 mg/ml) at pH 9 for 40 min at room temperature. Tc-IL2 was purified by solid phase extraction using a step-gradient elution with acidified ethanol. The radiochemical purity was also evaluated by thin-layer chromatography using ITLC-SGB strips (Gelman) and a scanning radiochromatograph. The strips were developed in acetone for measuring the presence of free 99m Tc. The strips were run in 12% trichloracetic acid (TCA) for measuring technetium colloid formation. Before injection into the patient, 99m Tc-IL2 (0.5 ml in phosphoric acid acidified ethanol) was diluted in 5 ml of a 5% glucose solution containing 0.3% of HSA (final pH 6).
In vivo studies
Informed consent was obtained from all patients and normal subjects studied. Approval for the project was obtained from the local Ethics Committee. Confidentiality of patient identification and data were maintained. Ten minutes before the study, normal subjects and patients received 200 mg of sodium perchlorate i.v. to prevent thyroid and stomach uptake of free 99m Tc possibly generated by the metabolism of 99m Tc-IL2.
Studies in normal volunteers
Eight healthy human volunteers (age 29.3±5 years, six males and two females) were injected with 99m
Tc-IL2 (16.1±8.9 μg, 42.6±13.9 MBq). Normal subjects, as requested by the ethics committee and in accordance to the guidance of ICRP62, were injected with a lower activity of 99m Tc-IL2, compared to patients, since in normal subjects the expected level of benefit is minimal and the level of exposure must be in category IIa (effective dose between 0.1 and 1 mSv). Dynamic images were acquired posteriorly for 45 min over the heart, liver, spleen and kidneys; static planar images of the chest and abdomen were obtained at 1, 2 and 4 h. Wholebody and thyroid scans were also acquired at the same time points, and radiation absorbed dose was calculated as described below. Heart rate, body temperature and blood pressure were monitored through the first hour of the study.
Serial blood samples at 5, 10, 15, 25, 35, 45, 60, 75, 120 and 240 min were taken to measure the plasma pharmacokinetics of the tracer, and TCA precipitation of plasma samples was performed. Blood samples taken 1, 3, 24, 72 and 132 h after the injection were used to investigate possible pharmacological effects of interleukin-2 on white blood cell count. Liver function tests, urea and electrolytes were also analysed before and 3 h after the injection. In one subject, a blood sample at 1 h was studied to determine the distribution of radioactivity in the whole blood.
Serial urine samples were taken up to 4 h for calculation of excreted activity and dosimetry calculations. Urine samples were precipitated with TCA for evaluation of 99m Tc-IL2 metabolism.
Studies in patients
Eight patients with Hashimoto thyroiditis, three with Graves' disease and one with primary hypothyroidism were studied. Diagnosis was based on the presence of thyroid autoantibodies (anti-thyroid peroxidase, anti-TSH receptor and anti-thyroglobulin), measurement of hormones (FT3, FT4 and TSH), 99m Tc-pertechnetate thyroid scan and clinical findings. At the time of the study, patients were recently diagnosed and were not receiving anti-thyroid drugs or other medications known to have an effect on lymphocyte activation.
Patients were injected i.v. with 110.2±96.9 MBq of 99m Tc-IL2 (40.2±11.7 μg). After the injection, dynamic images were acquired posteriorly for 45 min over the heart, liver, spleen and kidney. Static images were acquired at 1 and 3 h over the thyroid. Thyroid uptake of 99m Tc-IL2 was calculated by drawing a rectangular region of interest (ROI) around the organ; thyroid net counts were measured after subtraction of background activity calculated in a second rectangular ROI two pixels larger around the first; absolute thyroid uptake was calculated by converting the thyroid counts in activity according to the counting efficiency of the individual gamma camera. A semi-quantitative measurement of thyroid accumulation of 99m Tc-IL2 was also determined by calculating the thyroid to background ratio by drawing an irregular ROI over the thyroid and a rectangular ROI above the thyroid.
Blood samples were taken before and 10, 20, 40, 60 and 180 min after the injection of the radiopharmaceutical for calculation of blood clearance, TCA precipitation of plasma samples and evaluation of possible pharmacological or toxic effects.
Dosimetry calculations
In normal subjects, a set of anterior and posterior wholebody images, including a standard of known radioactivity, was acquired on a 512×512 matrix at different time points (typically 1, 2, 4 h) after administration of the radiopharmaceutical. Counts determined from the computer images corresponding to regions of interests drawn for the liver, spleen, kidneys, bladder and the standard were converted to activities.
The uptake in each organ was considered to be instantaneous; the clearance curves were obtained from the geometric mean of the anterior and posterior monoexponential fit to the activity-time curve corresponding to each of the above organs. The activity at time zero and the mean residence time from these clearance curves were then used in conjunction with the MIRD dosimetry system (IBM compatible, MIRDOSE 3, from Oak Ridge Associated Universities, 1994) to calculate the absorbed dose to each organ of interest, as well as to the whole body.
Measurement of urine excretion of 99m Tc-IL2
Urine was collected at 1, 2, 3 and 4 h after the injection of 99m Tc-IL2. For each collection, the total volume excreted was measured, and 1 ml was counted for radioactivity using an automated gamma counter (Ultragamma, LKB). The percentage of administered activity excreted in the urine was determined by measuring total excreted radioactivity compared with total activity injected after correction for decay from the time of measurement of the injected activity and for counting efficiency of the gamma counter (71%).
Results
Preparation of
99m Tc-IL2
The ligand was labelled to high specific activity with a labelling efficiency (LE) of 99% with no colloid formation. IL2 was labelled typically with a LE of 30%; about 30% of IL2, however, was retained by the cartridge, and the final labelling yield, after several passages and 2-h preparation, was about 10%. Starting with 3.7 GBq, the specific activity of 99m Tc-IL2 was about 5.7 MBq/μg. Quality controls showed a radiochemical purity greater than 95% and the absence of pyrogens and of microbial contamination.
Studies in normal volunteers
Studies in normal subjects showed fast plasma clearance. Kidneys were the major organs of accumulation of 99m Tc-IL2; the uptake increased up to 1 h and declined thereafter. Liver and spleen were also detectable. Some excretion in the bowel but no uptake in the thyroid or any other organ was observed (thyroid to background ratio: 1.06±0.05; Fig. 1, Table 1 ). TCA precipitation of plasma showed that most circulating radioactivity at 1 and 4 h was associated with 99m Tc-IL2 (Fig. 2) . TCA precipitation of the urine showed a lower degree of protein-bound radioactivity compared to plasma (Fig. 2) . Cumulative urinary excretion of 99m Tc-IL2 4 h p.i. was 26±5.7% of administered activity. Analysis of the distribution of radioactivity within whole blood revealed that 1.3% was associated with the WBC, 10% with the RBC and 88.7% with the plasma. No adverse effects from this dose of IL-2 were seen; no changes in heart rate, body temperature and blood pressure were observed; haematological changes were transient and within normal limits (Fig. 3) . No changes in platelet counts were observed. The effective dose equivalent (EDE) was calculated to be 7.3 μSv/MBq, i.e. 1.35 mSv for a typical diagnostic scan (185 MBq; Table 2 ).
Studies in patients
With respect to normal subjects, a higher accumulation of the tracer was observed in the spleen and liver of all patients (Fig. 4) . No accumulation in other abdominal organs and minimal intestinal excretion up to 3 h was observed (Fig. 5) . TCA precipitable activity of sera at 1 h was mostly protein bound (90.5±5.6%). Haematological changes were transient and within normal limits (Fig. 3) . No changes in platelet counts were observed. No side effects were observed.
Studies in patients showed a significant but variable degree of accumulation of Tc-IL2 on granulocytes (top graphs), lymphocytes (bottom graphs) in normal subjects (on the left) and in thyroid patients (on the right). All counts are within the normal range thyroid uptake at 1 h, 0.24 ± 0.09% i.d.; thyroid to background ratio at 1 h, 1.57±0.21; p<0.0005 vs normal subjects, Student's t test). Maximum uptake was seen at 1 h; thyroid uptake at 3 h was reduced by half in most patients. No correlation was noted between thyroid accumulation of 99m Tc-IL2 and autoantibody titre.
Discussion
The diagnosis of patients with autoimmune diseases is currently based on the measurements of autoantibodies directed against the target organ [5] .
Autoantibodies, however, are indirect markers with uncertain chronological relation with the underlying immune process as they may persist well after the end of the process [6] . They often have poor sensitivity since in a significant number of cases, they are not detectable in peripheral blood [6] . In vivo imaging of chronic inflammatory processes would help to overcome some of these limitations by providing direct evidence of the immune process and might contribute to the management of patients with autoimmune diseases [7, 8] . 123 I-labelled IL2 ( 123 I-IL2) has been shown to detect with high accuracy lymphocytic infiltration in a series of patients with immune-mediated diseases [2, 3] . Owing to, however, the cost of 123 I-IL2, only a limited number of Tc-IL2 patients can be studied; 123 I, moreover, is not readily available, and the preparation of 123 I-IL2 is a lengthy multistep procedure that requires the availability of a dedicated radiochemistry laboratory. It is, therefore, difficult to organise multi-centre trials to assess the real role of radiolabelled IL2 in a suitable number of patients. The availability of 99m Tc-IL2, preferably in the form of a singlestep kit, would greatly simplify the use of this technique.
We have developed a new technique for 99m Tc labelling of IL2 based on the use of an N 3 S bifunctional chelating agent with preserved in vitro receptor binding. The technique described in this paper provided high specific activity 99m Tc-IL2 for clinical use. The labelling procedure that was developed is multi-step and lengthy and does not represent a simplification over 123 I labelling of IL2. We are working on a simplified labelling technique with the aim to formulate a one-or two-step labelling kit.
In this paper, we assess the in vivo use of this new radiopharmaceutical and describe the biodistribution, kinetics, dosimetry, toxic profile and targeting capacity of 99m Tc-IL2 in normal subjects and in patients with autoimmune thyroid diseases.
A low EDE (1.35 mSv for a diagnostic activity equal to 185 MBq) and no toxic effects were observed. This is particularly important in follow-up studies when repeated injections are required, especially in view of the possible use of this radiopharmaceutical in paediatric subjects such as in patients with juvenile diabetes or coeliac disease. Studies in human, healthy volunteers showed high in vivo stability of 99m Tc-IL2, higher than previously shown with 123 I-IL2, rapid plasma clearance and low background radioactivity, comparable to that of 123 I-IL2. Kidneys were the major organs of accumulation of 99m Tc-IL2, which was excreted in the urine mostly in the form of low molecular weight metabolites, confirming previous studies in animals that demonstrated that IL2 is mainly metabolised in the kidneys [9] . No intestinal excretion was observed.
Compared to normal subjects, studies in patients showed an increased level of accumulation of 99m Tc-IL2 in the liver and, to a lesser extent, in the spleen. More than one mechanism could be advocated for this phenomenon. It is possible that, following the state of immune activation in patients with autoimmune diseases, a greater number of circulating IL2R+ve cells or a greater expression of IL2R is observed in lymphocytes homing into the liver and in the spleen. The binding of 99m Tc-IL2 to soluble IL2R, which has previously accumulated by the liver, is also possible, as well as liver uptake of circulating 99m Tc-IL2/sIL2R complexes. The sensitivity of 99m Tc-IL2 in pathologies of the liver and kidneys may, therefore, be reduced owing to its accumulation in the absence of local pathology. Abbs et al. have, nevertheless, been able to assess kidney graft Tc-IL2, expressed as thyroid to background ratio in patients with Hashimoto's thyroiditis, Graves' disease (and primary myxoedema) and normal subjects rejection by 123 I-IL2 in a rat model of kidney transplantation [10] .
No thyroid accumulation was seen in normal subjects, whereas in all patients with autoimmune thyroid diseases, a significant thyroid uptake of the tracer was observed, suggesting specific binding to IL2R+ve infiltrating lymphocytes. As a consequence of the rapid uptake of 99m Tc-IL2, image acquisition was completed within 2 h. Before the scan, it was necessary to prepare patients with sodium perchlorate to avoid possible interferences with free pertechnetate released by the metabolism of 99m Tc-IL2. This was well tolerated and did not give any side effect.
Thyroid infiltration by activated lymphocytes has been reported in patients with autoimmune thyroid diseases [11, 12] . Previous studies with 111 In-labelled lymphocytes demonstrated accumulation in patients with Hashimoto's thyroiditis but not in patients with Graves' disease [13] . This may depend on the clonal in situ expansion of infiltrating lymphocytes in Graves' disease with no migration from circulating lymphocytes [12] . In the present study, however, 99m Tc-IL2 accumulated in the thyroid of patients with Graves' disease, probably as a consequence of the easy penetration of a small molecule like IL2 in sites of chronic inflammation where the vascular permeability is not greatly increased and access to lymphocytes is more difficult. Thyroid uptake in patients with Hashimoto's thyroiditis was greater compared to that observed in patients with Graves' disease. It is known that both diseases are characterised by lymphocytic infiltration, but in Hashimoto's thyroiditis, the density of thyroid-infiltrating lymphocytes is much higher than in Graves' disease [11, 12] . This is in accordance with our results; a large overlap exists, however, between the degrees of accumulation of the radiotracer in the thyroid of either group (Fig. 6) , suggesting that 99m Tc-IL2 can be used for assessing the activity of the disease but not for discriminating between Hashimoto's and Graves' disease.
In Graves' disease patients, a correlation between microsomal autoantibodies and the intensity of the intrathyroidal autoimmune process has been reported [14] . No correlation was noted, however, in this study between thyroid accumulation of 99m Tc-IL2 and autoantibody titre. Although no definitive conclusions can be drawn from the study of this small number of patients, the results obtained so far suggest that there is no direct correlation between humoral-mediated and cell-mediated immunity in autoimmune thyroid diseases. In the three patients with active Graves' disease and exophthalmos, no clear accumulation of 99m Tc-IL2 was noted in the retroorbital space. Lymphocytic infiltration of the retroorbital space has been reported in patients with Graves' disease, and ophthalmopathy and the presence of some cytokines (interferon-γ, IFN-γ, tumour necrosis factor β and interleukin-1α has been reported in the orbital connective tissue of these patients, but the presence of IL2 and of IL2R positive cells is still a matter of debate [15, 16] . It is also possible that a transient, time-related expression of the IL2R occurs and that expression of IL2R might only be observed in the early phases of exophthalmos. This has already been reported for 111 In-octreotide, which showed accumulation in the retroorbital space of patients with exophthalmos only during the early phases of the disease [17, 18] . Finally, a sensitivity problem cannot be ruled out due to the limited amount of radioactivity (about 100 MBq) injected in our patients. Indeed, Rendl et al., using 123 I-IL2 and injecting much higher activities (about 370 MBq), were able to image the retroorbital infiltration, as well as the pre-tibial myxoedema, better than with 111 In-octreoscan in patients with Graves' disease [19] . A controlled study in a larger number of patients is necessary to address this point.
Conclusion
These preliminary results suggest that scintigraphy with 99m Tc-IL2 is simple and safe. Its rapid clearance and favourable dosimetry and biodistribution make it a suitable technique for in vivo imaging of disease activity in patients with autoimmune thyroid diseases and might be used to confirm the immune nature in doubtful cases. Larger studies are in progress in several pathologies to assess the role of 99m Tc-IL2 in the clinical management of autoimmune patients.
